Kamada Ltd (KMDA) reports a 13% revenue increase and unveils plans for biosimilar launches and plasma center expansions.

Q4 2024 Earnings Call Transcript March 5, 2025 EyePoint Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-0.64 EPS, expectations were $-0.54. Tessa Romero – JPMorgan: Yigal ...

Record Year with Total 2024 Revenues of $161.0 Million, Representing a 13% Increase over Fiscal Year 2023 and Adjusted EBITDA ...

Q4 2024 Earnings Call Transcript March 5, 2025 Kamada Ltd. beats earnings expectations. Reported EPS is $0.07, expectations ...

Moderna, Inc.'s stock soars 16% amid patent win over Pfizer/BioNTech, while legal battles highlight mRNA challenges. Click ...

Wall Street is generally afraid of uncertainty, but with adversity also comes opportunity. Find out my 2 picks that have well ...

Topline interim dataset from GALAXIES Lung-201 with >240 patients anticipated in 2Q25- Interim datasets from GALAXIES H&N-202 and ...

Organogenesis ( ORGO -5.54%) Q4 2024 Earnings Call Feb 27, 2025, 5:00 p.m. ET ...

Clinical data presented at SITC 2024 supports further development of COM701, potential first-in-class anti-PVRIG antibody <li /> On track ...

Clinical data presented at SITC 2024 supports further development of COM701, potential first-in-class anti-PVRIG antibody On track to initiate a randomized adaptive ...